A clinical trial supported by the National Institutes of Health (NIH) found that adults with prediabetes assigned to a lifestyle intervention had a significantly lower risk of developing multiple chronic health conditions ...
4 hours ago
0
0
One of the largest real-world studies of people taking GLP-1 medications found women, those without pre-existing conditions such as type 2 diabetes and high blood pressure, and behavioral factors such as previously setting ...
7 hours ago
0
1
Tirzepatide doesn't just help people lose weight; it also activates brown adipose tissue, representing a major milestone in obesity research, according to a study presented at ENDO 2026, the Endocrine Society's annual meeting ...
7 hours ago
0
1
Researchers are warning that obesity is reshaping the global cardiovascular disease crisis, as trend data covering 204 countries reveal that heart disease now peaks in people ages 50–54 rather than the elderly and increasingly ...
10 hours ago
0
1
Metabolic and bariatric surgery for teens with severe obesity was found to be cost-effective over 10 years, according to a new analysis from Ann & Robert H. Lurie Children's Hospital of Chicago published in JAMA Network Open. ...
11 hours ago
0
2
GLP-1 medications are marketed to help you lose weight, but one may be better at it than the rest, according to a new meta-analysis from the University of Georgia.
11 hours ago
0
6
GLP-1s do not harm male hormones or fertility after long-term use, according to a study being presented Monday at ENDO 2026, the Endocrine Society's annual meeting in Chicago. In fact, the research team found GLP-1s may improve ...
12 hours ago
0
2
Lifestyle-induced loss of visceral fat (and not liver fat, pancreatic fat or subcutaneous fat) may have lasting health benefits years after the end of an intervention, even when body weight is fully regained, according to ...
Jun 14, 2026
0
9
In people with type 2 diabetes, semaglutide was associated with a 15% reduction in bone fractures and greater weight loss compared with other anti-obesity medications, according to a study presented at ENDO 2026, the Endocrine ...
Jun 14, 2026
0
6
Adults with obesity who lost weight with glucagon-like peptide-1 (GLP-1) receptor agonist medications significantly decreased their physical activity, which is essential to protect muscle, according to a study presented at ...
Jun 13, 2026
0
7
